Hot Life Science Mandate 3: Opportunistic Institutional Alternative Investor Investing Globally

9 Jan

Allocation Information

The life science investment subsidiary of a major investment group has assets under management of $400m and is investing from its second fund, which closed at roughly  $300m in 2012. The firm typically makes initial equity investments of $3-7m with the potential to invest up to $20m over the life of an investment.  While most of the firm’s portfolio companies are US-based the firm will consider opportunities worldwide.

Sectors & Subsectors of Interest

The firm invests opportunistically across the life science sector, and is active in the therapeutic, diagnostic and medical device sectors. The firm prefers to invest in companies with products in the late preclinical stage (typically about 12 months from IND; animal data is required).  In the case of medical devices, companies that have developed a prototype and obtained FIM data are of interest. While not all investments are made at this stage, the firm prefers to build relationships with companies at an early stage. The investor will consider investing in any indication.

Company & Management Team Requirements

The firm invests in both experienced management teams, as well as new entrepreneurs and is open to investing in both privately-held and public companies.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: